Free Trial
ASX:PAB

Patrys (PAB) Stock Price, News & Analysis

Patrys logo

About Patrys Stock (ASX:PAB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
250,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Receive PAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

PAB Stock News Headlines

Patrys Limited AGM Resolutions Successfully Passed
Patrys Limited Shifts Focus to Promising PAT-DX3 Development
“Trump Trades” You’ve Got to Make
These Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to pop now that Donald Trump has been re-elected
3 ASX Penny Stocks With Market Caps Over A$9M To Consider
Patrys Limited Shifts Focus to Promising Antibody PAT-DX3
Patrys Limited Announces Virtual AGM for 2024
Patrys Limited
See More Headlines

PAB Stock Analysis - Frequently Asked Questions

Patrys Limited (ASX:PAB) announced its quarterly earnings data on Wednesday, February, 20th. The company reported $0.00 earnings per share (EPS) for the quarter. Patrys had a negative net margin of 253.85% and a negative trailing twelve-month return on equity of 68.67%.

Company Calendar

Last Earnings
2/20/2019
Today
11/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-3,540,000.00
Net Margins
-253.85%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.39 million

Miscellaneous

Outstanding Shares
2,060,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.42
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (ASX:PAB) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners